#USA #Denver #financial results #DaVita Inc. #Q4 2025

DaVita Inc. Financial Results for 4th Quarter 2025

Overview

On February 2, 2026, DaVita Inc. (NYSE: DVA) released its financial and operational results for the fourth quarter and full year ending December 31, 2025. The company’s performance showcases resilience and innovation in providing quality kidney care despite ongoing challenges in the healthcare environment.

Financial Highlights

Consolidated Revenues

DaVita reported consolidated revenues of $3.620 billion for the fourth quarter and $13.643 billion for the entire year.

Operating Income

• - Operating income for Q4 was $561 million, with an adjusted operating income of $586 million.
• - For the year, the operating income reached $2.044 billion, with an adjusted figure of $2.094 billion.

Earnings Per Share

• - Diluted earnings per share (EPS) from continuing operations stood at $2.94 for Q4 and $9.51 for the year.
• - Adjusted diluted EPS was $3.40 for Q4 and $10.78 for the whole fiscal year.

Cash Flow

• - Operating cash flow was $541 million for the last quarter, summing up to $1.887 billion for the year.
• - Free cash flow was $309 million and $1.024 billion respectively for Q4 and the full year.

Strategic Investments and Share Repurchase

In line with enhancing its operational robustness, DaVita refinanced its existing Term Loan and revolving line of credit during Q4 FY2025. The company repurchased approximately 2.7 million shares of common stock at an average price of $122.78 per share during this period, emphasizing its confidence in sustaining financial health and increase shareholder value.

Operational Metrics

• - The company provided dialysis services to roughly 295,000 patients across 3,242 outpatient centers.
• - Total U.S. dialysis treatments during the fourth quarter were 7,264,520, averaging about 91,608 treatments per day.

Operational Challenges

Despite commendable financial highlights, DaVita faced operational challenges like a nearly 0.6% decrease in normalized non-acquired treatment growth year-over-year. These metrics emphasize the competitive dynamics and market pressures present in the healthcare sector.

Future Outlook

As DaVita looks ahead to 2026, CEO Javier Rodriguez expressed optimism regarding the company’s strategic investments and operational processes, expecting continued success in maintaining both clinical quality and financial performance. DaVita looks to guide its performance amid the complex healthcare landscape, focusing on enhancing patient care and operational practices.

Conclusion

DaVita Inc.'s financial results for Q4 2025 reflect a strong commitment to delivering innovative and quality care, further enhancing its position within the healthcare industry. As the company advances towards 2026, its financial strategies and operational improvements indicate a promising outlook for ongoing growth and success.